FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2030984096> ?p ?o ?g. }

• W2030984096 endingPage "582" @default.
• W2030984096 startingPage "579" @default.
• W2030984096 abstract "HomeCirculationVol. 128, No. 6Atheroprone Flow Activation of the Sterol Regulatory Element Binding Protein 2 and Nod-Like Receptor Protein 3 Inflammasome Mediates Focal Atherosclerosis Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBAtheroprone Flow Activation of the Sterol Regulatory Element Binding Protein 2 and Nod-Like Receptor Protein 3 Inflammasome Mediates Focal Atherosclerosis Jun-ichi Abe, MD, PhD and Bradford C. Berk, MD, PhD Jun-ichi AbeJun-ichi Abe From the Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY. Search for more papers by this author and Bradford C. BerkBradford C. Berk From the Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY. Search for more papers by this author Originally published9 Jul 2013https://doi.org/10.1161/CIRCULATIONAHA.113.004390Circulation. 2013;128:579–582Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: August 6, 2013: Previous Version 1 Atheroprone flow promotes inflammation in endothelial cells, and this process is critical for pathogenesis of many chronic inflammatory conditions such as coronary and carotid artery atherosclerosis, as well as abdominal aortic aneurysm. Signal mediators activated by atheroprone (disturbed) flow that have been described include nuclear factor κB and protein kinase ζ, which is very different from atheroprotective (steady laminar) flow.1 In this issue of Circulation, an article from Xiao et al2 shows the critical role of sterol regulatory element binding protein 2 (SREBP2) on atheroprone flow–mediated Nod-like receptor protein 3 (NLRP3) inflammasome activation. In particular, they showed that atheroprone flow induced both mature form of SREBP2 (SREBP2-N) and SREBP2 mRNA induction, which transcriptionally increase NADPH oxidase 2 (Nox2) and NLRP3 expression, thereby leading to interleukin 1β (IL-1β) expression and endothelial inflammation (Figure 1). In this editorial, we briefly review the NLRP3 inflammasome and SREBP activation system, which play a key role in modulating atheroprone flow–mediated endothelial cell inflammation. We also discuss the following important considerations for the future: the role of local NLRP3 and IL-1β expression, mechanisms for two different types of flow (atheroprone flow versus atheroprotective flow) on SREBP2 activation, and other NLRP3 activators including thioredoxin-interacting protein (TXNIP).Download figureDownload PowerPointFigure 1. Scheme for sterol regulatory element binding protein 2 (SREBP2)-mediated Nod-like receptor protein 3 (NLRP3) inflammasome activation. IL indicates interleukin; Nox, NADPH oxidase; ROS, reactive oxygen species; and TXNIP, thioredoxin-interacting protein.Article see p 632The inflammasome is a protein complex that serves as a platform for the maturation of caspase-1 subsequent activation, leading to proteolytic maturation and secretion of IL-1β and IL-18 (Figure 8 in Xiao et al2). Three essential components of inflammasome are a sensor protein, the adapter protein ASC, and the inflammatory protease caspase-1. As a sensor protein, Nod-like receptor (NLR) family (NLRP1, NLRP3, and NLRP4) and AIM2 function as pathogen sensors and form an inflammasome complex. NLRP3 is unique in that it responds to numerous diverse physical and chemical triggers, unlike other NLRP members. NLRP3 also integrates concomitant stresses of cell damage present during inflammation, such as extracellular adenosine triphosphate (ATP), reactive oxygen species (ROS), uric acid crystals, cholesterol crystals, and IAPP (islet amyloid polypeptide).3,4 In the current study, Xiao et al have shown that atheroprone flow (oscillatory flow) increased NLRP3 expression and subsequent cleaved caspase-1 and IL-1β expression compared with pulsatile shear flow in vitro. The authors also found that the levels of the cleaved caspase-1, IL-1β, and NLRP3 were higher in the aortic arch (predominantly exposed to atheroprone flow) than thoracic aorta in vivo, supporting the crucial role of atheroprone flow–induced NLRP3 inflammasome activation on the development of atherosclerosis. The induction of NLRP3 and Nox2 by SREBP2 transactivation is proposed as a novel mechanism of atheroprone flow effects.However, the evidence for the role of NLRP3 activation during the process of atherosclerosis is controversial5–7 (Figure 1). Cholesterol crystal in the plaque itself can activate NLRP3 inflammasome and release IL-1β from mouse and human macrophages.6 Cholesterol crystals are recognized as a hallmark of atherosclerotic lesions. Although crystals are prevalent in advanced atherosclerotic lesions, Duewell et al6 have reported that cholesterol crystals were not only detected in necrotic cores but also in subendothelial areas that are rich in immune cells, even in an early stage of atherosclerosis. Depletion of NLRP3 or ACS in macrophages inhibits cholesterol crystal–mediated caspase-1 cleavage and IL-1β release and subsequent atherosclerosis formation in the background of low-density lipoprotein receptor knockout mice (LDLR−/−). These data support the crucial role of NLRP3 inflammasome complex in cholesterol crystals-mediated inflammation and atherosclerosis.6 However, these results have been challenged by the recent publication from Menu et al,7 which showed no differences of atherosclerosis between double knock mice of Nlrp3−/− crossed with ApoE−/− mice and control ApoE−/− mice.7 Two notable differences of those studies are (1) LDLR−/− versus ApoE−/− mice, and (2) knock out from bone marrow–derived cells versus whole body. In this current issue, Xiao et al nicely showed that endothelial-specific SREBP2 deficiency inhibited NLRP3 induction and atherosclerosis in the ApoE−/− background.2 But because the function of NLRP3 inflammasome in vessel wall, including endothelial cells, especially in ApoE−/− background, remains unclear, it will be crucial to determine the role of endothelial NLRP3 inflammasome in atherosclerosis.The importance of NLRP3 inflammasome in the process of atherosclerosis has been supported by several studies that focus on IL-1β. In IL-1β–deficient mice crossed with atherogenic apolipoprotein E knockout mice (ApoE−/−), a significant decrease in atherosclerosis with stabilization of the atherosclerosis plaque was exhibited. Importantly, treatment of ApoE−/− mice with IL-1 receptor antagonists also significantly inhibits atherosclerosis.5 To evaluate the clinical efficacy of this concept, the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) has been ongoing.8 The purpose of this study is to evaluate the effect of IL-1β inhibition by canakinumab (a human monoclonal antibody that selectively neutralizes IL-1β) as compared with placebo on recurrent myocardial infarction, stroke, and cardiovascular death among stable patients with coronary artery disease who show persistent elevation of high sensitivity C-reactive protein despite contemporary prevention strategies.8SREBPs, including SREBP-1a, -1c, and 2, regulate the transcription of a number of genes involved in the cellular sterol and lipid homeostasis. In particular, SREBP2 is ubiquitously expressed, and relatively selective activator of cholesterol synthesis, as opposed to fatty acid synthesis, and regulates HMG-CoA reductase and low-density lipoprotein receptor genes.9,10 Because low levels of cholesterol stimulate SREBPs, the crucial role of SREBPs on liver steatosis and hyperlipedemia has been reported.9,11 However, the other roles of SREBPs in innate immunity and autophagy, which are not directly related with lipid homeostatis, have also been reported.12,13 The functions of SREBP in endothelial cells unrelated to lipid homeostatis remain unclear. To our knowledge, this is the first report to show SREBP2 regulates endothelial inflammation via increasing NLRP3 and Nox2 expression, which is not directly related to the regulation of lipid homeostatis.2Importance of shear stress in vascular biology and pathophysiology is highlighted by the fact that steady laminar flow is protective against atherosclerosis, whereas disturbed flow is a strong risk factor of the disease.1 Previously, the authors have reported that atheroprone flow can cause sustained SREBP1 activation with nuclear localization. In contrast, atheroprotective flow also temporarily increased nuclear transport, but could not be sustained.14 SREBPs are bHLH-LZ family transcription factors, and inactive precursors (pre-SREBPs) of newly synthesized SREBPs are cleaved subsequently by proteases, then release the SREBPs NH2-terminal portion of SREBPs (SREBP-N; Figure 2). This mature form of SREBP-N enters the nucleus and binds the sterol regulatory element 1 (SRE-1), and increases target genes expression9 (Figure 2). Therefore, there are 2 possible steps by which flow can regulate SREBP activation. The first is the process of pre-SREBPs cleavage in the extranucleus, and the second is nuclear SREBP-N transcriptional activity regulation. In the current issue, Xiao et al showed the acceleration of the process of pre-SREBPs cleavage, which is the first step of SREBP activation, by showing the increased level of SREBP-N induced by atheroprone flow. In the Discussion, the possible involvement of Akt induced by atheroprone flow was suggested by the authors, but because Akt directly regulates nuclear SREBP-N, which is the second step of SREBPs activation as we will explain below (Figure 2), further evaluation will be necessary.Download figureDownload PowerPointFigure 2. Scheme for sterol regulatory element binding protein (SREBP) activation regulated by 2 different types of flow (atheroprone flow vs atheroprotective flow). Akt indicates v-akt thymoma viral oncogene homolog; AMPK, AMP-activated protein kinase; bHLH, basic helix-loop-helix; GSK, glycogen synthase kinase; mTORC, mammalian target of rapamycin complex; NLRP, Nod-like receptor protein; Nox, NADPH oxidase; SIRT, Sirtulin; and SRE, sterol regulatory element.Recently, the role of posttranslational modification on the regulation of SREBP activation has been discussed.12 Insulin increases SREBP-N transcriptional activity via activating phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin complex 1 (mTORC1) kinase pathway.12 Furthermore, Akt activation inhibits GSK3 kinase activation, which leads to ubiquitination and proteosomal degradation of the active transcription factor of SREBP-N by direct phosphorylation. In contrast to Akt, the inhibitory effect of AMP-activated protein kinase (AMPK) and Sirtulin1 (SIRT1) on SREBP activation has been reported.12 SREBP can be directly phosphorylated by AMPK, leading to suppress protein processing and nuclear translocation, and repress target gene expression, and SIRT1 directly deacetylates SREBP-1c and increases its degradation.12 Of note, Dr Shyy’s group has previously reported the specific activation of AMPK and induction of SIRT1 by atheroprotective flow15 (Figure 2). However, it is not clear whether atheroprone flow–mediated Akt activation can explain sustained activation and nuclear localization of SREBP, and atheroprotective flow-induced AMPK and SIRT1 induction inhibit these events. These issues, including the specificity of each flow’s pattern differences on SREBP activation, need to be clarified in future studies. As mentioned above, because cholesterol crystal formation was observed in subendothelial areas in an early stage of atherosclerosis, atheroprone flow–induced SREBP2 activation may accelerate cholesterol crystal formation, which may indirectly activate NLRP3 inflammasome.Our group has reported that atheroprone flow increased TXNIP expression.16 TXNIP can promote atherosclerosis by multiple mechanisms.17 These data are relevant because it has been reported that ROS induced TXNIP-NLRP3 association, and TXNIP deficiency inhibited ROS-mediated NLRP3 inflammasome activation.18 Therefore, it is possible that atheroprone flow–induced TXNIP expression may be involved to this NLRP3 inflammasome activation. However, because other reports were unable to reproduce some of TXNIP function on NLRP3,4,19 further investigation is necessary (Figure 1). Furthermore, although the crucial role of ROS on NLRP3 inflammasome activation has been well established, the source and type of inflammasome-activating ROS is under controversy (Figure 1). It is very intriguing that Xiao et al showed the crucial role NADPH oxidase 2 (Nox2 on caspase-1 activation and IL-1β expression in endothelial cells in the current article. However, the idea of the involvement of Nox on NLRP3 inflammasome activation was not supported in macrophages.4,20 The deletion of Nox1, Nox2, and Nox4 in macrophages did not show any defect in inflammasome activation. The macrophage-deficient Nox2 showed robust decrease of ROS production, but only a minimum reduction in inflammasome activation. Instead, ROS generated by mitochondria having reduced mitochondria membrane potential leads to NLRP3 inflammasome activation.4,20 Of note, mitochondria is also very sensitive to ROS, which disrupts the electron respiratory chain, and further increases ROS production. The contribution of Nox family and mitochondrial ROS production on endothelial NLRP3 inflammasome activation needs further investigation.In conclusion, Xiao et al have shown that atheroprone flow–mediated SREBP2 activation increases NLRP3 inflammasome activation via increasing NLRP3 and Nox2 expression, leading to endothelial inflammation and atherosclerosis formation. Previously, the authors’ group showed the unique sustained SREBP nuclear localization induced by atheroprone flow but not by atheroprotective flow, supporting the critical role of SREBP2 activation under atheroprone flow, but the mechanisms by which the atheroprone flow but not atheroprotective flow activates SREBP activation need further clarification. In addition, the contribution of endothelial NLRP3 inflammasome on atherosclerosis, and source of ROS, which activates endothelial NLRP3, will be important to understand. It is clear that atheroprone flow–mediated endothelial inflammation is a highly regulated process that is increasingly as attractive a target for therapeutic intervention as steady laminar flow–mediated atheroprotective pathways.Sources of FundingThis study was supported by grants from the National Institutes of Health to Drs Berk (HL-064839, HL 106158) and Abe (HL-064839, HL-108551, HL-102746).DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to Jun-ichi Abe, MD, PhD, Aab Cardiovascular Research Institute, Box CVRI, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Rochester, NY 14642. E-mail [email protected]References1. Heo KS, Fujiwara K, Abe J. Disturbed-flow-mediated vascular reactive oxygen species induce endothelial dysfunction.Circ J. 2011; 75:2722–2730.CrossrefMedlineGoogle Scholar2. Xiao H, Lu M, Lin TY, Chen Z, Chen G, Wang WC, Marin T, Shentu TP, Wen L, Gongol B, Sun W, Liang X, Chen J, Huang HD, Pedra JHF, Johnson DA, Shyy JYJ. Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility.Circulation. 2013; 128:632–642.LinkGoogle Scholar3. Kanneganti TD. Central roles of NLRs and inflammasomes in viral infection.Nat Rev Immunol. 2010; 10:688–698.CrossrefMedlineGoogle Scholar4. Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view.Immunol Rev. 2011; 243:136–151.CrossrefMedlineGoogle Scholar5. Wen H, Ting JP, O’Neill LA. A role for the NLRP3 inflammasome in metabolic diseases–did Warburg miss inflammation?Nat Immunol. 2012; 13:352–357.CrossrefMedlineGoogle Scholar6. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.Nature. 2010; 464:1357–1361.CrossrefMedlineGoogle Scholar7. Menu P, Pellegrin M, Aubert JF, Bouzourene K, Tardivel A, Mazzolai L, Tschopp J. Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome.Cell Death Dis. 2011; 2:e137.CrossrefMedlineGoogle Scholar8. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).Am Heart J. 2011; 162:597–605.CrossrefMedlineGoogle Scholar9. Xiao X, Song BL. SREBP: a novel therapeutic target.Acta Biochim Biophys Sin (Shanghai). 2013; 45:2–10.CrossrefMedlineGoogle Scholar10. Daemen S, Kutmon M, Evelo CT. A pathway approach to investigate the function and regulation of SREBPs.Genes Nutr. 2013; 8:289–300.CrossrefMedlineGoogle Scholar11. Tang JJ, Li JG, Qi W, Qiu WW, Li PS, Li BL, Song BL. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques.Cell Metab. 2011; 13:44–56.CrossrefMedlineGoogle Scholar12. Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism.Cell Metab. 2012; 16:414–419.CrossrefMedlineGoogle Scholar13. Im SS, Yousef L, Blaschitz C, Liu JZ, Edwards RA, Young SG, Raffatellu M, Osborne TF. Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a.Cell Metab. 2011; 13:540–549.CrossrefMedlineGoogle Scholar14. Liu Y, Chen BP, Lu M, Zhu Y, Stemerman MB, Chien S, Shyy JY. Shear stress activation of SREBP1 in endothelial cells is mediated by integrins.Arterioscler Thromb Vasc Biol. 2002; 22:76–81.LinkGoogle Scholar15. Chen Z, Peng IC, Cui X, Li YS, Chien S, Shyy JY. Shear stress, SIRT1, and vascular homeostasis.Proc Natl Acad Sci U S A. 2010; 107:10268–10273.CrossrefMedlineGoogle Scholar16. Wang XQ, Nigro P, World C, Fujiwara K, Yan C, Berk BC. Thioredoxin interacting protein promotes endothelial cell inflammation in response to disturbed flow by increasing leukocyte adhesion and repressing Kruppel-like factor 2.Circ Res. 2012; 110:560–568.LinkGoogle Scholar17. Spindel ON, World C, Berk BC. Thioredoxin interacting protein: redox dependent and independent regulatory mechanisms.Antioxid Redox Signal. 2012; 16:587–596.CrossrefMedlineGoogle Scholar18. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation.Nat Immunol. 2010; 11:136–140.CrossrefMedlineGoogle Scholar19. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z, Mullooly N, Mielke LA, Harris J, Coll RC, Mills KH, Mok KH, Newsholme P, Nuñez G, Yodoi J, Kahn SE, Lavelle EC, O’Neill LA. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes.Nat Immunol. 2010; 11:897–904.CrossrefMedlineGoogle Scholar20. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation.Nature. 2011; 469:221–225.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By He L, Zhang C, Chen Q, Wang L and Huang Y (2022) Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2022.108152, 235, (108152), Online publication date: 1-Jul-2022. von Ehr A, Bode C and Hilgendorf I (2022) Macrophages in Atheromatous Plaque Developmental Stages, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2022.865367, 9 El Hadri K, Smith R, Duplus E and El Amri C (2021) Inflammation, Oxidative Stress, Senescence in Atherosclerosis: Thioredoxine-1 as an Emerging Therapeutic Target, International Journal of Molecular Sciences, 10.3390/ijms23010077, 23:1, (77) Libby P (2021) Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1, Interleukin-6 and Beyond, Cells, 10.3390/cells10040951, 10:4, (951) Sazonova M, Sinyov V, Ryzhkova A, Sazonova M, Kirichenko T, Khotina V, Khasanova Z, Doroschuk N, Karagodin V, Orekhov A and Sobenin I (2021) Some Molecular and Cellular Stress Mechanisms Associated with Neurodegenerative Diseases and Atherosclerosis, International Journal of Molecular Sciences, 10.3390/ijms22020699, 22:2, (699) Chen X, Guo X, Ge Q, Zhao Y, Mu H and Zhang J (2019) ER Stress Activates the NLRP3 Inflammasome: A Novel Mechanism of Atherosclerosis, Oxidative Medicine and Cellular Longevity, 10.1155/2019/3462530, 2019, (1-18), Online publication date: 7-Oct-2019. Hua H, Yang T, Huang L, Chen R, Li M, Zou Z, Wang N, Yang D and Liu Y (2019) Protective Effects of Lanosterol Synthase Up-Regulation in UV-B-Induced Oxidative Stress, Frontiers in Pharmacology, 10.3389/fphar.2019.00947, 10 de Gaetano M, McEvoy C, Andrews D, Cacace A, Hunter J, Brennan E and Godson C (2018) Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications, Frontiers in Pharmacology, 10.3389/fphar.2018.01488, 9 Gopoju R, Panangipalli S and Kotamraju S (2018) Metformin treatment prevents SREBP2-mediated cholesterol uptake and improves lipid homeostasis during oxidative stress-induced atherosclerosis, Free Radical Biology and Medicine, 10.1016/j.freeradbiomed.2018.02.031, 118, (85-97), Online publication date: 1-Apr-2018. Libby P (2017) Interleukin-1 Beta as a Target for Atherosclerosis Therapy, Journal of the American College of Cardiology, 10.1016/j.jacc.2017.09.028, 70:18, (2278-2289), Online publication date: 1-Oct-2017. Park S, Kim J, Yu M, Park J, Kim Y and Moon Y (2016) Epithelial Cholesterol Deficiency Attenuates Human Antigen R-linked Pro-inflammatory Stimulation via an SREBP2-linked Circuit, Journal of Biological Chemistry, 10.1074/jbc.M116.723973, 291:47, (24641-24656), Online publication date: 1-Nov-2016. Bao M, Luo H, Chen L, Tang L, Ma K, Xiang J, Dong L, Zeng J, Li G and Li J (2016) Impact of high fat diet on long non-coding RNAs and messenger RNAs expression in the aortas of ApoE(−/−) mice, Scientific Reports, 10.1038/srep34161, 6:1, Online publication date: 1-Oct-2016. Shimokawa H, Sunamura S and Satoh K (2016) RhoA/Rho-Kinase in the Cardiovascular System, Circulation Research, 118:2, (352-366), Online publication date: 22-Jan-2016.Lee Y, Wakita D, Dagvadorj J, Shimada K, Chen S, Huang G, Lehman T, Fishbein M, Hoffman H, Crother T and Arditi M (2015) IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model, Arteriosclerosis, Thrombosis, and Vascular Biology, 35:12, (2605-2616), Online publication date: 1-Dec-2015. Wang G, Liu K, Li Y, Yi W, Yang Y, Zhao D, Fan C, Yang H, Geng T, Xing J, Zhang Y, Tan S, Yi D and Câmara N (2014) Endoplasmic Reticulum Stress Mediates the Anti-Inflammatory Effect of Ethyl Pyruvate in Endothelial Cells, PLoS ONE, 10.1371/journal.pone.0113983, 9:12, (e113983) Padilla J, Jenkins N, Thorne P, Martin J, Rector R, Davis J and Laughlin M (2014) Identification of genes whose expression is altered by obesity throughout the arterial tree, Physiological Genomics, 10.1152/physiolgenomics.00091.2014, 46:22, (821-832), Online publication date: 15-Nov-2014. August 6, 2013Vol 128, Issue 6 Advertisement Article InformationMetrics © 2013 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.113.004390PMID: 23838164 Originally publishedJuly 9, 2013 Keywordssignal transductioninflammationinflammasomesSREBP proteinsEditorialsPDF download Advertisement SubjectsAnimal Models of Human DiseaseCell Signaling/Signal TransductionPathophysiology" @default.
• W2030984096 created "2016-06-24" @default.
• W2030984096 creator A5034101987 @default.
• W2030984096 creator A5038661951 @default.
• W2030984096 date "2013-08-06" @default.
• W2030984096 modified "2023-09-24" @default.
• W2030984096 title "Atheroprone Flow Activation of the Sterol Regulatory Element Binding Protein 2 and Nod-Like Receptor Protein 3 Inflammasome Mediates Focal Atherosclerosis" @default.
• W2030984096 cites W1593760300 @default.
• W2030984096 cites W1605844554 @default.
• W2030984096 cites W1972483153 @default.
• W2030984096 cites W1985538633 @default.
• W2030984096 cites W1992479323 @default.
• W2030984096 cites W2015031752 @default.
• W2030984096 cites W2018607502 @default.
• W2030984096 cites W2022621797 @default.
• W2030984096 cites W2026212701 @default.
• W2030984096 cites W2034946303 @default.
• W2030984096 cites W2035528560 @default.
• W2030984096 cites W2047597908 @default.
• W2030984096 cites W2063700981 @default.
• W2030984096 cites W2074115529 @default.
• W2030984096 cites W2083984814 @default.
• W2030984096 cites W2104448262 @default.
• W2030984096 cites W2132872115 @default.
• W2030984096 cites W2151367512 @default.
• W2030984096 cites W2159728029 @default.
• W2030984096 doi "https://doi.org/10.1161/circulationaha.113.004390" @default.
• W2030984096 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4091715" @default.
• W2030984096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23838164" @default.
• W2030984096 hasPublicationYear "2013" @default.
• W2030984096 type Work @default.
• W2030984096 sameAs 2030984096 @default.
• W2030984096 citedByCount "19" @default.
• W2030984096 countsByYear W20309840962014 @default.
• W2030984096 countsByYear W20309840962015 @default.
• W2030984096 countsByYear W20309840962016 @default.
• W2030984096 countsByYear W20309840962017 @default.
• W2030984096 countsByYear W20309840962018 @default.
• W2030984096 countsByYear W20309840962019 @default.
• W2030984096 countsByYear W20309840962021 @default.
• W2030984096 countsByYear W20309840962022 @default.
• W2030984096 crossrefType "journal-article" @default.
• W2030984096 hasAuthorship W2030984096A5034101987 @default.
• W2030984096 hasAuthorship W2030984096A5038661951 @default.
• W2030984096 hasBestOaLocation W20309840961 @default.
• W2030984096 hasConcept C126322002 @default.
• W2030984096 hasConcept C134018914 @default.
• W2030984096 hasConcept C170493617 @default.
• W2030984096 hasConcept C2777209026 @default.
• W2030984096 hasConcept C2778163477 @default.
• W2030984096 hasConcept C2778718757 @default.
• W2030984096 hasConcept C555293320 @default.
• W2030984096 hasConcept C55851684 @default.
• W2030984096 hasConcept C71924100 @default.
• W2030984096 hasConcept C85051948 @default.
• W2030984096 hasConcept C86803240 @default.
• W2030984096 hasConcept C95444343 @default.
• W2030984096 hasConceptScore W2030984096C126322002 @default.
• W2030984096 hasConceptScore W2030984096C134018914 @default.
• W2030984096 hasConceptScore W2030984096C170493617 @default.
• W2030984096 hasConceptScore W2030984096C2777209026 @default.
• W2030984096 hasConceptScore W2030984096C2778163477 @default.
• W2030984096 hasConceptScore W2030984096C2778718757 @default.
• W2030984096 hasConceptScore W2030984096C555293320 @default.
• W2030984096 hasConceptScore W2030984096C55851684 @default.
• W2030984096 hasConceptScore W2030984096C71924100 @default.
• W2030984096 hasConceptScore W2030984096C85051948 @default.
• W2030984096 hasConceptScore W2030984096C86803240 @default.
• W2030984096 hasConceptScore W2030984096C95444343 @default.
• W2030984096 hasIssue "6" @default.
• W2030984096 hasLocation W20309840961 @default.
• W2030984096 hasLocation W20309840962 @default.
• W2030984096 hasLocation W20309840963 @default.
• W2030984096 hasLocation W20309840964 @default.
• W2030984096 hasOpenAccess W2030984096 @default.
• W2030984096 hasPrimaryLocation W20309840961 @default.
• W2030984096 hasRelatedWork W2030984096 @default.
• W2030984096 hasRelatedWork W2033437499 @default.
• W2030984096 hasRelatedWork W2130716475 @default.
• W2030984096 hasRelatedWork W2196876291 @default.
• W2030984096 hasRelatedWork W2396184234 @default.
• W2030984096 hasRelatedWork W2889028407 @default.
• W2030984096 hasRelatedWork W3003665331 @default.
• W2030984096 hasRelatedWork W3014463361 @default.
• W2030984096 hasRelatedWork W3016528077 @default.
• W2030984096 hasRelatedWork W4229805117 @default.
• W2030984096 hasVolume "128" @default.
• W2030984096 isParatext "false" @default.
• W2030984096 isRetracted "false" @default.
• W2030984096 magId "2030984096" @default.
• W2030984096 workType "article" @default.